(VIANEWS) – BOIRON (BOI.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| BOIRON (BOI.PA) | €40.25 | 2.74% | 8.13% |
| CEGEDIM (CGM.PA) | €19.60 | 2.56% | 5.08% |
| EQUASENS (EQS.PA) | €73.50 | 1.47% | 28.59% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. BOIRON (BOI.PA)
2.74% Forward Dividend Yield and 8.13% Return On Equity
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary, proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; and Sédatif PC to treat anxiety and emotional, and minor sleep disorders. The company's homeopathic medicines also comprise Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; and Homéovox for vocal disorders. In addition, it provides dietary supplement; Dermoplasmine stick, baume, and mousse to treat dry lips and skin; Mag' Nuit, a formula to fall asleep; Arnitrosium for joint pain; Castor Equi Boiron ointment for treatment of cracked skin; and Storinyl, a syrup to treat colds. Further, it offers herbal medicines, such as Canephron to increase the amount of urine and to improve urinary elimination; moisturizing baby milk; and medical devices, including a range of COVID self-tests and rapid antigenic tests. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
Earnings Per Share
As for profitability, BOIRON has a trailing twelve months EPS of €2.89.
PE Ratio
BOIRON has a trailing twelve months price to earnings ratio of 13.93. Meaning, the purchaser of the share is investing €13.93 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.13%.
Moving Average
BOIRON’s worth is under its 50-day moving average of €40.39 and under its 200-day moving average of €44.40.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BOIRON’s stock is considered to be oversold (<=20).
More news about BOIRON.
2. CEGEDIM (CGM.PA)
2.56% Forward Dividend Yield and 5.08% Return On Equity
Cegedim SA operates as a technology and services company in the digital data flow management for healthcare ecosystem and B2B, and business software publisher for healthcare and insurance professionals worldwide. It operates in two divisions, Health Insurance, HR and e-Services; and Healthcare Professionals. The Health Insurance, HR and e-Services division markets various products and services to insurance companies, mutual insurers, personal protection insurers, and insurance brokers, as well as engages in the interactions between these entities and healthcare professionals. This division also provides solutions for hosting, HR and payroll management outsourcing, and electronic data exchange services. The Healthcare Professionals division offers management software, databases, and solutions to doctors, allied health professionals, pharmacists, and healthcare facilities. The company was incorporated in 1969 and is headquartered in Boulogne-Billancourt, France. Cegedim SA is a subsidiary of FCB SA.
Earnings Per Share
As for profitability, CEGEDIM has a trailing twelve months EPS of €1.03.
PE Ratio
CEGEDIM has a trailing twelve months price to earnings ratio of 19.03. Meaning, the purchaser of the share is investing €19.03 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.08%.
Volatility
CEGEDIM’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.42%, a positive 0.17%, and a positive 1.35%.
CEGEDIM’s highest amplitude of average volatility was 2.34% (last week), 1.24% (last month), and 1.35% (last quarter).
Volume
Today’s last reported volume for CEGEDIM is 2725 which is 25.17% below its average volume of 3642.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jun 29, 2022, the estimated forward annual dividend rate is 0.5 and the estimated forward annual dividend yield is 2.56%.
More news about CEGEDIM.
3. EQUASENS (EQS.PA)
1.47% Forward Dividend Yield and 28.59% Return On Equity
Equasens Société anonyme provides various IT solutions for the healthcare sector in Europe. It offers LGPI global services and OffiCentral solutions for managing pharmacies and their networks; OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, OffiCash, Offizzy, and OffiLocker solutions for pharmacists' business processes; and solutions for energizing the customer relationship with pharmacists comprising OffiTag, OffiTouch, OffiMédia, OffiConnect, automation systems, and customer loyalty programs. The company also provides My Pilot, an analytics and management tool; OffiLearning, an e-learning tool; and solutions for patient support and advice, such as compliance monitoring software, Multimeds, Automeds, and OffiTéléconsult, as well as pharmaceutical record and shared medical record services. In addition, it offers a ULTIMATE, a system combining optimized pharmacy management and improved patient support; FARMACLICK, a protocol for communications between pharmacies and wholesalers-distributors; DIFARM, a solution for wholesalers-distributors; PHARE, a retail management tool; SOPHIA, a pharmacy management application; OffiMédia POS display; eNephro to enhance the care of chronic renal failure patients; and TPE Pilot, a web-based application that simplifies the management and sharing of patient education programs. Further, the company provides NOVIACARE; CARELIB Domicile; CARELIB EHPAD; KAPELSE solutions; TITAN solutions; ANTHADINE software and MOBISOINS mobile tool; MICROSOINS, an in-home nursing care solution; and LOGICLIC. Additionally, it offers AXIGATE solutions to manage the entire patient care pathway; CHORUS platform; medical telesecretarial services for healthcare professionals; and equipment lease financing solutions. The company was incorporated in 1996 and is based in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.
Earnings Per Share
As for profitability, EQUASENS has a trailing twelve months EPS of €3.05.
PE Ratio
EQUASENS has a trailing twelve months price to earnings ratio of 24.1. Meaning, the purchaser of the share is investing €24.1 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.59%.
Volatility
EQUASENS’s last week, last month’s, and last quarter’s current intraday variation average was 0.14%, 0.12%, and 1.22%.
EQUASENS’s highest amplitude of average volatility was 1.49% (last week), 1.05% (last month), and 1.22% (last quarter).
Moving Average
EQUASENS’s value is under its 50-day moving average of €73.71 and below its 200-day moving average of €74.79.
Sales Growth
EQUASENS’s sales growth for the current quarter is 7%.
Volume
Today’s last reported volume for EQUASENS is 1218 which is 66.34% below its average volume of 3619.
More news about EQUASENS.
